Victoria E R Parker
Overview
Explore the profile of Victoria E R Parker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
878
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Daniels S, Karlsson C, Schrauwen P, Parker V
Trends Endocrinol Metab
. 2025 Feb;
PMID: 39934020
Identification of exendin-4 (a glucagon-like peptide 1 receptor agonist, GLP-1RA) in Gila monster venom may be regarded as one of the most serendipitous discoveries of recent times. GLP-1RAs are now...
2.
Selvarajah V, Robertson D, Hansen L, Jermutus L, Smith K, Coggi A, et al.
Kidney Int
. 2024 Sep;
106(6):1170-1180.
PMID: 39218393
Cotadutide is a glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist that may improve kidney function in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). In this phase...
3.
White T, Selvarajah V, Wolfhagen-Sand F, Svangard N, Mohankumar G, Fenici P, et al.
Diabetes Obes Metab
. 2024 Apr;
26(7):2722-2731.
PMID: 38618987
Aim: Hypertension and diabetes mellitus (DM) are major causes of morbidity and mortality, with growing burdens in low-income countries where they are underdiagnosed and undertreated. Advances in machine learning may...
4.
Parker V, Robertson D, Erazo-Tapia E, Havekes B, Phielix E, de Ligt M, et al.
Nat Metab
. 2023 Dec;
5(12):2086-2093.
PMID: 38066113
Cotadutide is a dual glucagon-like peptide 1 and glucagon receptor agonist under development for the treatment of non-alcoholic steatohepatitis and type 2 diabetes mellitus (T2DM) and chronic kidney disease. Non-alcoholic...
5.
Lee N, Kiddle S, Chandankhede S, Agrawal S, Bean D, Hunt P, et al.
BMJ Open Gastroenterol
. 2023 Nov;
10(1).
PMID: 38030407
Objective: Cirrhosis describes the end-stage of chronic liver disease. Irreversible changes in the liver cause portal hypertension, which can progress to serious complications and death. Only a few studies with...
6.
Mercier A, Sunnaker M, Ueckert S, Pawlik T, Henricson E, Molodetskyi O, et al.
Clin Pharmacokinet
. 2023 Oct;
62(12):1713-1724.
PMID: 37801266
Background And Objective: Zibotentan, a selective endothelin A receptor antagonist, is in development for chronic liver and kidney disease. The pharmacokinetics (PK) of zibotentan were previously investigated in patients with...
7.
Parker V, Hoang T, Schlichthaar H, Gibb F, Wenzel B, Posch M, et al.
Diabetes Obes Metab
. 2022 Apr;
24(7):1360-1369.
PMID: 35403793
Aim: To assess the efficacy, safety and tolerability of cotadutide in patients with type 2 diabetes mellitus and chronic kidney disease. Materials And Methods: In this phase 2a study (NCT03550378),...
8.
Carmignac V, Mignot C, Blanchard E, Kuentz P, Aubriot-Lorton M, Parker V, et al.
Genet Med
. 2021 Jul;
23(8):1585.
PMID: 34257424
No abstract available.
9.
Carmignac V, Mignot C, Blanchard E, Kuentz P, Aubriot-Lorton M, Parker V, et al.
Genet Med
. 2021 Apr;
23(8):1484-1491.
PMID: 33833411
Purpose: Hypomelanosis of Ito (HI) is a skin marker of somatic mosaicism. Mosaic MTOR pathogenic variants have been reported in HI with brain overgrowth. We sought to delineate further the...
10.
Parker V, Robertson D, Wang T, Hornigold D, Petrone M, Cooper A, et al.
J Clin Endocrinol Metab
. 2019 Oct;
105(3).
PMID: 31608926
Context: Cotadutide is a dual receptor agonist with balanced glucagon-like peptide-1 and glucagon activity. Objective: To evaluate different doses of cotadutide and investigate underlying mechanisms for its glucose-lowering effects. Design/setting:...